Leaflet Modification for Redo-TAVR: Impact of Valve Type, Expansion, and Failure Mode-A Bench Study
Listen to this summary
This study investigates the factors influencing the efficacy of leaflet modification techniques in redo transcatheter aortic valve replacement (TAVR), specifically examining how valve type, annular constraint, flow conditions, and leaflet degeneration affect outcomes. The authors found that leaflet splay varies significantly based on these factors, with different transcatheter heart valves responding uniquely to modification techniques. Overall, the results highlight the complexity of achieving effective leaflet modification in redo-TAVR procedures.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from JACC. Cardiovascular interventions
View all →Jun 9, 2026 · JACC. Cardiovascular interventions
Impact of Tissue Treatment and Leaflet Design on Fifth-Generation Balloon-Expandable Transcatheter Heart Valve Function
Jun 9, 2026 · JACC. Cardiovascular interventions
Comparison of Leaflet Modification Techniques for TAV-in-TAV: Insights From Bench Testing
Jun 9, 2026 · JACC. Cardiovascular interventions
A Proposed Anatomical-Fluoroscopic Workflow to Identify the Optimal Split Line for Leaflet Modification in Redo-TAVR
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
